Drug
sildenafil 100mg
sildenafil 100mg is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
33%
Ph not_applicable
1
33%
Ph phase_3
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Other(2)
Detailed Status
Suspended1
unknown1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (33.3%)
Phase 31 (33.3%)
N/A1 (33.3%)
Trials by Status
suspended133%
unknown133%
completed133%
Recent Activity
0 active trials
Showing 3 of 3
suspendedphase_3
Phosphodiesterase Inhibitors in Glaucoma Study (PhiGS)
NCT04052269
unknownnot_applicable
Early Start of Oral Sildenafil 100mg for Erectile Dysfunction After Robotic Assisted Laparoscopic Radical Prostatectomy
NCT01054001
completedphase_2
A Randomized Double Blind, Placebo Controlled Balanced 4-Way Crossover Study To Assess The Efficacy Of Single Oral Doses
NCT00273416
Clinical Trials (3)
Showing 3 of 3 trials
NCT04052269Phase 3
Phosphodiesterase Inhibitors in Glaucoma Study (PhiGS)
NCT01054001Not Applicable
Early Start of Oral Sildenafil 100mg for Erectile Dysfunction After Robotic Assisted Laparoscopic Radical Prostatectomy
NCT00273416Phase 2
A Randomized Double Blind, Placebo Controlled Balanced 4-Way Crossover Study To Assess The Efficacy Of Single Oral Doses
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3